SCHEMBL25617815

SCHEMBL25617815

CCCN(CCOS(C)(=O)=O)c1c(C)cc([N+](=O)[O-])cc1S(=O)(=O)N1CCN(Cc2cccnc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 2/20 0.38
MAPT P10636 4/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 3/20 0.36
GFER P55789 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GAA P10253 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35
DRD3 P35462 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25617750 0.93 ALDH1A1 (0.41) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617827 0.91 POLB (0.41) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617808 0.91 ALDH1A1 (0.48) ALDH1A1CYP3A4CYP2C9CYP2C19POLB
SCHEMBL25618117 0.91 ALDH1A1 (0.37) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617973 0.91 ALDH1A1 (0.37) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617618 0.89 ALDH1A1 (0.41) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617813 0.89 MAPT (0.39) ALDH1A1POLBMAPTLMNAPKM
SCHEMBL25617806 0.87 ALDH1A1 (0.46) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617678 0.86 ALDH1A1 (0.45) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19
SCHEMBL25617818 0.86 ALDH1A1 (0.43) ALDH1A1KDM4ECYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661404-B2 Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders ACHILLES MEDICAL LIMITED (NZ) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661404-B2 Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders AKR1C2, AKR1C1, AKR1B1 ALDH1A1 61/4885KDM4E 2709/4885CYP3A4 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.